Vaxart Files Proxy Materials, No Fee Required
Ticker: VXRT · Form: DEFA14A · Filed: May 12, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, regulatory
Related Tickers: VXRT
TL;DR
Vaxart filed proxy docs, no fee. Standard procedure.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials (DEFA14A) on May 12, 2025. This filing relates to the company's proxy statement and indicates no fee was required for this filing. Vaxart, Inc. is a biotechnology company focused on biological products.
Why It Matters
This filing provides important information to shareholders regarding company matters, as required by the SEC for public companies.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating any immediate financial or operational risks.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- 0001437749-25-015961 (filing_id) — Accession Number
- May 12, 2025 (date) — Filing Date
- DEFA14A (document_type) — Form Type
FAQ
What type of filing is this?
This is a Definitive Additional Materials (DEFA14A) filing.
Who is the filing company?
The filing company is Vaxart, Inc.
When was this filing submitted?
The filing was submitted on May 12, 2025.
Was a fee required for this filing?
No fee was required for this filing.
What is Vaxart, Inc.'s primary business?
Vaxart, Inc. is in the business of Biological Products (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 12, 2025 regarding Vaxart, Inc. (VXRT).